APEPTICO invited to visit the Bio Industry EXPO 2014 in Osong, Korea

Following successful participation of APEPTICO at the EU-Korea Conference on Science and Technology (EKC, Vienna, July 2014), APEPTICO has been invited by the Korea Trade-Investment Agency (KOTRA) to present its bio-pharmaceutical innovations at the Bio Industry EXPO 2014 in Osong, Korea.

The Bio Industry Expo is a “one in ten years only” event hosted by the Korean Ministry of Trade, Industry & Energy.
For three weeks between September 26th and October 12th 2014, the 170,000 square-meter Osong Bio Valley will exhibit the most cutting-edge developments in biotechnology. The mission of the Bio Industry Expo is to combine international and national biotechnology research and development. During the Bio Industry Expo, 665,000 Korean and 35,000 foreign life science engineers and scientists from 163 Korean and 60 foreign bio-industry companies will meet to discover "The Secret of Life & Beautiful Future”.
Dr. Bernhard Fischer, CEO of APEPTICO stated ”We are very proud  to have been selected by KOTRA to present APEPTICO as one of the most innovative Austrian biotechnology companies at the Bio Industry Expo”. “During the event, we will meet with numerous Korean biotech and pharma companies to discuss synergies and future collaboration developments” he added.
About APEPTICO GmbH (www.apeptico.com)
APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids general risks associated with gene- and cell-technologies. APEPTICO makes use of its technology platforms PEPBASE(TM) and PEPSCREEN(TM) to significantly reduce cost and to shorten time to market.
About the AP301-peptide / TIP-peptide
APEPTICO actively develops the AP301-peptides. Comprehensive research and development studies conducted the APEPTICO research consortium demonstrated, that AP301-peptides are effective therapeutic molecules in various forms of pulmonary oedema, such as pulmonary permeability and hydrostatic oedema, high altitude pulmonary oedema (HAPE), pulmonary oedema associated with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), pulmonary oedema resulting from pneumonia, sepsis and lung transplantation (primary graft dysfunction).
The AP301-peptides (synonym to TNF-derived TIP-peptide) are synthetic molecules whose structures are based on the lectine-like domain of the human Tumour Necrosis Factor-alpha. The AP301 peptide is water soluble and can be administered into the lung by oral inhalation. Formulated AP301 is easily nebulised and the resulting aerosol is composed of peptide/water droplets of diameter 4 μm or less. APEPTICO’s most recent clinical phase II proof-of-concept studies demonstrated that orally inhaled AP301-peptide activates alveolar liquid clearance in mechanically ventilated patients with pulmonary permeability oedema, and ARDS and is effective in patients following lung transplantation.
APEPTICO’s AP301 has been granted orphan drug status (i) for treatment of pulmonary permeability oedema in ALI/ARDS, (iii) for treatment of primary graft dysfunction following lung, and (iii) for treatment of high altitude pulmonary oedema by the European Commission and European Medicines Agency (EMA) and by the Food and Drug Agency (FDA).
About pulmonary oedema
Pulmonary oedema occurs when fluid leaks from the pulmonary capillary network into the lung interstitium and alveoli. There are many possible causes of lung oedema, such as heart failure (cardiac/hydrostatic lung oedema); inhaling high concentrations of smoke, toxins, or oxygen; severe burns; blood infections / sepsis; infection of the lung / pneumonia; aspirations, cerebral damage or trauma to other parts of the body and lung transplantation. Lungs contain alveoli, which are tiny air sacs where the oxygen is passed into the blood. During lung oedema, blood and fluid begin to leak into the alveoli. When this happens, oxygen cannot enter the alveoli, which means oxygen no longer passes into the blood. Because the lungs are inflamed and filled with fluid, the patient finds it increasingly difficult to breathe. The mortality rate of patients with pulmonary oedema in ALI/ARDS is 35% to 45% within two to four weeks. Currently, no specific drug treatment exists for patients suffering from pulmonary permeability oedema and patients having ARDS. ARDS is also a major economic burden to hospitals and health care budgets. It is estimated that due to a long ICU and hospital stay the cost of every saved live from ARDS is approximately $70,000 USD.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.